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Cyclin-dependent kinases (CDKs) drive cell cycle
progression and control transcriptional processes. The dysregulation of multiple CDK family
members occurs commonly in human cancer; in
particular, the cyclin D-CDK4/6-retinoblastoma
protein (RB)-INK4 axis is universally disrupted,
facilitating cancer cell proliferation and prompting long-standing interest in targeting CDK4/6
as an anticancer strategy. Most agents that
have been tested inhibit multiple cell cycle and
transcriptional CDKs and have carried toxicity.
However, several selective and potent inhibitors
of CDK4/6 have recently entered clinical trial.
PD0332991, the first to be developed, resulted
from the introduction of a 2-aminopyridyl substituent at the C2-position of a pyrido(2,3-d)
pyrimidin-7-one backbone, affording exquisite selectivity toward CDK4/6.1 PD0332991
arrests cells in G1 phase by blocking RB phosphorylation at CDK4/6-specfic sites and does
not inhibit the growth of RB-deficient cells.2
Phase I studies conducted in patients with
advanced RB-expressing cancers demonstrated
mild side effects and dose-limiting toxicities
of neutropenia and thrombocytopenia, with
prolonged stable disease in 25% of patients.3,4
In cyclin D1-translocated mantle cell lymphoma,
PD0332991 extinguished CDK4/6 activity in
patients’ tumors, resulting in markedly reduced
proliferation, and translating to more than 1
year of stability or response in 5 of 17 cases.5
Two recent papers from the Knudsen
laboratory make several important observations that will help guide the continued
clinical development of CDK4/6 inhibitors. In
the study by Dean et al., surgically resected
patient breast tumors were grown on a tissue
culture matrix in the presence or absence of
PD0332991. Crucially, these cultures retained
associated stromal components known to
play important roles in cancer pathogenesis
and therapeutic sensitivities, as well as key
histological and molecular features of the primary tumor, including expression of ER, HER2
and Ki-67. Similar to results in breast cancer
cell lines,6 the authors demonstrate that only
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RB-positive tumors have growth inhibition in
response to PD0332991, irrespective of ER or
HER2 status, while tumors lacking RB were
completely resistant. This result underscores
RB as the predominant target of CDK4/6 in
breast cancer cells and the primary marker
of drug response in primary patient-derived
tumors. As expected, RB-negative tumors
routinely demonstrated robust expression of
p16INK4A; however, p16INK4A expression was not
always a surrogate marker for RB loss, supporting the importance of direct screening
of tumors for RB expression to select patients
appropriate for CDK4/6 inhibitor clinical trials.
In the second study, McClendon et
al. investigated the efficacy of PD0332991
in combination with doxorubicin in triplenegative breast cancer cell lines. Again, RB
functionality was paramount in determining
response to either PD0332991 monotherapy
or combination treatment. In RB-deficient
cancer cells, CDK4/6 inhibition had no effect
in either instance. However, in RB-expressing
cancer cells, CDK4/6 inhibition and doxorubicin provided a cooperative cytostatic effect,
although doxorubicin-induced cytotoxicity
was substantially reduced, assessed by markers for mitotic catastrophe and apoptosis.
Additionally, despite cytostatic cooperativity,
CDK4/6 inhibition maintained the viability of
RB-proficient cells in the presence of doxorubicin, which repopulated the culture after
removal of drug. These results reflect previous
data demonstrating that ectopic expression of
p16INK4A can protect cells from the lethal effects
of DNA damaging and anti-mitotic chemotherapies.7 Similar results have been reported
in MMTV-c-neu mice bearing RB-proficient
HER2-driven tumors, where PD0332991 compromised carboplatin-induced regressions,8
suggesting that DNA-damaging treatments
should not be combined concomitantly with
CDK4/6 inhibition in RB-proficient tumors.
To combine CDK4/6 inhibition with cytotoxics, sequential treatment may be considered, in which CDK4/6 inhibition is followed by
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DNA damaging chemotherapy; cells relieved
of G1 arrest may synchronously enter S phase,
where they may be most susceptible to agents
disrupting DNA synthesis. Release of myeloma
cells from a prolonged PD0332991-mediated
G1 block leads to S phase synchronization;
interestingly, all scheduled gene expression
is not completely restored (including factors
critical to myeloma survival such as IRF4), further favoring apoptotic responses to cytotoxic
agents.9 Furthermore, in RB-deficient tumors,
CDK4/6 inhibitors may be used to maximize
the therapeutic window between transformed
and non-transformed cells treated with chemotherapy. In contrast to RB-deficient cancer cells, RB-proficient non-transformed cells
arrested in G1 in response to PD0332991 are
afforded protection from DNA damaging
agents, thereby reducing associated toxicities,
including bone marrow suppression.8
In summary, the current work provides
evidence for RB expression as a determinant
of response to CDK4/6 inhibition in primary
tumors and highlights the complexity of combining agents targeting the cell cycle machinery with DNA damaging treatments.
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ORCA is regulated by ubiquitin-mediated degradation to control Orc2 function
Comment on: Shen Z, et al. Cell Cycle 2012; 11:3578–89;
PMID:22935713; http://dx.doi.org/10.4161/cc.21870

Amy E. Ikui; Brooklyn College; Brooklyn, NY USA; Email: AIkui@brooklyn.cuny.edu; http://dx.doi.org/10.4161/cc.22391

Eukaryotic cells ensure that DNA is replicated
only once per cell cycle. The initiation of DNA
replication is dependent on the formation of
the pre-replicative complex (pre-RC) on replication origins. The six components of origin
recognition complex (Orc1–6p) are bound to
the origins, followed by Cdc6p, Cdt1p and the
Mcm2–7p complex, to constitute pre-RC. The
pre-RC is then activated by the Dbf kinaseCdc7p complex to initiate DNA replication,
where the Mcm complex acts as a helicase.1
After initiation, the pre-RC complex is disassembled and/or inactivated in order to inhibit
re-initiation until the next cell cycle. The inhibition of the pre-RC assembly can be achieved
by protein degradation through ubiquitination, translocation and/or phosphorylation of
the pre-RC components. Regulation of the Orc
complex across species is diverse. In yeast, the
Orc complex is probably associated on the
origin throughout the cell cycle, and the Orc
proteins are phosphorylated by cyclin/CDK
complex to inhibit the function.2 In humans,
Orc1 is ubiquitinated by SCFskp2 complex and
degraded by the proteasome.3 Orc2 is associated with heterochromatin, centromere
and centrosome depending on the cell cycle
stage.3,4
Previously Shen et al. showed that Orcassociated protein (ORCA) utilizes WD40
repeats to associate with DNA replication factors such as Orc, Cdt1 and Geminin in human
cells. The WD40 repeats in ORCA are also
required for chromatin binding, suggesting
that ORCA may anchor other DNA replication
factors to chromatin. ORCA stabilizes Orc to
chromatin, indicating that ORCA positively
regulates the initiation of DNA replication.5
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Figure 1. A model: cell cycle-dependent control of ORCA determines Orc2 binding to origin.

The siRNA treatment against Orc2 showed
decreased amount of ORCA, suggesting
that the stability of ORCA is dependent on
Orc2.6 Therefore, the Orc2-ORCA binding
facilitates the stability of this complex. It has
been shown that ORCA protein levels are
peaked at G1 phase. In a previous issue of Cell
Cycle, Shen et al. investigated the molecular
mechanism by which ORCA is regulated in a
cell cycle-dependent manner.7 The authors
showed that ORCA is polyubiquitinated at
the WD40 repeat region, where it is recognized by Orc2. They observed an elevated
ORCA ubiquitination level at G1/S boundary
that coincides with ORCA protein degradation. Furthermore, Orc2 is associated only with
non-ubiquinated ORCA, indicating that Orc2
prevents ORCA from ubiquitin-mediated degradation. The authors proposed a model that
Orc2 releases from chromatin after G1, which
may trigger ORCA ubiquitination and degradation (Fig. 1). Therefore, ORCA degradation
prevents Orc2 loading on the chromatin after
G1 to allow only one S-phase per cell cycle.
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This cell cycle-dependent ORCA regulation
may allow Orc2 to obtain diverse functions
as well as timely initiation of DNA replication
on the specific origins. The novel mechanism
to control Orc components through ORCA
may be a key mechanism to control DNA
re-replication.
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New functions for ecotropic viral integration site 1 (EVI1), an oncogene causing
aggressive malignant disease
Comment on: Karakaya K, et al. Cell Cycle 2012; 11:3492–503;
PMID:22894935; http://dx.doi.org/10.4161/cc.21801
Rotraud Wieser; Department of Medicine I and Comprehensive Cancer Center; Medical University of Vienna; Vienna, Austria;
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The oncogene Evi1, which codes for a
sequence-specific transcription factor, was
cloned as a target of activating retroviral insertions in murine myeloid tumors 24 y ago.1 Soon
thereafter, its human homolog was found to
be transcriptionally activated through rearrangements of chromosome band 3q26,2,3
which are associated with a poor prognosis in acute myeloid leukemia (AML).4 Since
then, EVI1 has emerged repeatedly as retroviral
integration site in different organisms, and a
role of its overexpression as an indicator of
poor prognosis in a variety of hematopoietic
malignancies, as well as some solid tumors,
has been firmly established. Because of its
well-documented clinical importance, understanding the mechanism(s) of action of EVI1
is of high significance. However, EVI1 reveals
its secrets only slowly, with merely 475 articles
containing the search terms “EVI1,” “EVI-1” or
“MECOM” (the officially assigned, but still rarely
used, gene name) deposited in PubMed at the
time of writing.
One of the most recent occasions on
which EVI1 gained negative prominence was
in the context of a human gene therapy trial
for X-linked chronic granulomatous disease
(X-CGD).5 Transplantation of gene-modified,
autologous hematopoietic stem cells initially
provided substantial clinical benefit to two
young adults with X-CGD. However, over
time, hematopoiesis became dominated by
clones with vector integrations into, and transcriptional activation of, the EVI1 locus. These
clones finally evolved into myeloid malignancies, acquiring monosomy 7, a chromosome
aberration frequently associated with EVI1
overexpression in AML, during this process.
As a preliminary mechanistic explanation for
these findings, experimental expression of
EVI1 in human diploid fibroblasts increased
the numbers of cells with aberrant centrosome
numbers.5
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In the September 15th issue of Cell Cycle,
Karakaya and colleagues confirmed and
extended these observations.6 Using U2OS
osteosarcoma cells inducibly expressing EVI1
as a model, they show that only 72 h after
induction of EVI1, 17% of the cells contained
centrosome amplifications vs. 5% of the control cells. Analysis of nuclear morphology and
time-lapse video microscopy suggested that
supernumerary centrosomes resulted from a
cytokinesis defect that is known to activate
a p53-dependent tetraploidy checkpoint.
Indeed, induction of EVI1 upregulated p53
and siRNA-mediated p53 depletion increased
the percentage of polyploid cells after EVI1
induction. Furthermore, the vast majority of
EVI1-overexpressing cells with centrosome
amplification had low or undetectable levels
of the proliferation marker Ki67, indicating
that EVI1-induced centrosome aberrations
were largely confined to cells in G0 or early G1,
and confirming that EVI1-induced tetraploidization caused a cell cycle arrest.6
These data, together with those from the
X-CGD study,5 establish genomic instability as
a not previously reported consequence of EVI1
overexpression, which also might explain its frequent association with monosomy 7. It should
be pointed out, though, that chromosome
aberrations can also emerge through selection
on the background of normal missegregation
rates rather than through increased genetic
instability.7 In fact, in the Mitelman database,8
in ~39% of AML cases with a 3q26 aberration
this was the sole cytogenetic anomaly, and for
~82% of 3q26 rearranged cases, only a single
clone was reported [compared with ~43%
and ~83%, respectively, for the prognostically favorable t(8;21)(q22;q22)]. These data
do not argue for greatly increased rates of
chromosome instability as a consequence of
EVI1 overexpression. However, excessive instability would likely pose the danger of lethal

Cell Cycle

genetic aberrations and thus not be beneficial
to a tumor cell, while low-level instability may
become apparent from cytogenetic data only
through more detailed analyses. In addition
to eventual subtle effects on karyotype at
the time of diagnosis, modest EVI1-induced
chromosome instability raises the intriguing
possibility that EVI1 overexpression may cause
poor prognosis at least in part by facilitating
acquisition of aberrations that allow tumor
cells to escape chemotherapy-induced apoptosis. This hypothesis can be tested through
quantitative evaluation of chromosome aberrations and clones at diagnosis and relapse
(which is caused by cells that survived the
initial therapy) in patients with 3q26 rearranged/EVI1 overexpressing AML and suitable
controls. The work of Karakaya et al., in addition to the novel information it provides as
it stands, therefore opens new perspectives
that may lead to substantial advances in our
understanding of how overexpression of EVI1
contributes to poor prognosis in AML and
other malignancies.
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Addicted to PAR? A closer look at PARP inhibitor sensitivity
Comment on: Oplustilova L, et al. Cell Cycle 2012; 11:3837–50;
PMID:22983061; http://dx.doi.org/10.4161/cc.22026
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Defects in genome maintenance and repair
pathways are common features of human cancers. In some cases, specific DNA repair defects
can render cancer cells dependent on back-up
pathways for their survival, and targeting these
back-up mechanisms is a promising strategy
for cancer therapy.1 One example for such synthetic lethality is the pronounced sensitivity of
BRCA-deficient cancer cells, defective in DNA
repair by homologous recombination (HR),
to inhibition of poly(ADP-ribose) polymerases
(PARPs).2 Consequently, PARP inhibitors have
entered clinical trials as single agents, but
also in combination therapy as chemo- or
radiation-sensitizing drugs.3 Following exciting proof-of-concept results, however, PARP
inhibitors recently encountered first difficulties, and the current challenge is to understand why certain cancers respond better to
these compounds than others.
In a study now published in Cell Cycle,
Oplustilova and colleagues used a panel of
human cancer cell lines derived from carcinomas of breast, prostate, colon, pancreas and
ovary to study the response to PARP inhibition
and analyze cellular determinants of sensitivity
or resistance.4
Acquired resistance by drug efflux can
be a major barrier to therapeutic efficacy,
and Oplustilova et al. demonstrate that
P-glycoprotein drug efflux pumps contribute
to inhibitor resistance in colon cancer cells,
thereby extending previous findings obtained
in a mouse model for BRCA1-associated
breast cancer.5 Importantly, inhibition of
P-glycoprotein by verapamil resulted in elevated intracellular levels of the PARP inhibitor
KU 58948 and restored inhibitor sensitivity,
consolidating the notion that acquired resistance by enhanced drug efflux can, in principle, be overcome.
The authors also investigated a second
mechanism of alleviated PARP inhibitor
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sensitivity based on the recent discovery that
loss of the genome caretaker 53BP1 restores
HR in BRCA1-deleted cells.6,7 Consistent with
the proposed function of 53BP1 to restrict DNA
end resection, exacerbate HR deficiency and
enhance PARP inhibitor sensitivity, Oplustilova
et al. show that shRNA-mediated depletion of
53BP1 in a human BRCA1-defective breast cancer cell line reduced sensitivity to PARP inhibition. Given the aberrant reduction of 53BP1
in subsets of BRCA-associated breast carcinomas and sporadic triple-negative breast cancers,7 immunohistochemical analyses of 53BP1
expression, as also performed in the present
study, might thus have predictive value when
assessing PARP inhibitor sensitivity.
Intrigued by the emerging notion that the
concept of synthetic lethality could have wider
applicability to other defects in the DNA damage response network, and in line with previous studies demonstrating PARP inhibitor
sensitivity associated with BRCA-independent
HR defects,8 Oplustilova et al. show that even
partial depletion of the MRN components
MRE11 or NBS1 sensitizes to PARP inhibition,
whereas ectopic expression in mutant cells
had the opposite effect.
Further, arguing that ongoing PARP activity must be a prerequisite for PARP inhibitors
to work, Oplustilova et al. went on to assess
steady-state poly(ADP-ribose) (PAR) levels in
different cell lines and report a correlation
between detection of PAR and inhibitor sensitivity. While these results generally support
PAR levels as potential candidate biomarker,
additional studies are needed to determine
whether PAR detection is technically feasible
in tissue biopsies, and whether PARP inhibitor sensitivity is inevitably associated with
detectable amounts of PAR, especially in light
of the limited sensitivity of the available antibodies for shorter PAR chains. Likewise, when
Oplustilova et al. assessed RAD51 foci numbers
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as a surrogate marker for HR, several cell lines
were sensitive to PARP inhibition, yet they
had normal RAD51 foci levels, suggesting that
either specific HR defects do not entail reduced
RAD51 loading, or that synthetic lethality can
be achieved through HR-independent mechanisms. Together, these results raise the concern
that use of single biomarkers could indeed be
misleading, and that a combination of markers
to assess which cancer cells are likely “addicted
to PAR” might be more reliable. The study by
Oplustilova et al. evaluates several of such candidate biomarkers and thus contributes to the
collective effort to guide targeted cancer therapy to those patients who might benefit most
from PARP inhibitor treatment. However, it also
illustrates once again that such guidance crucially relies on a more detailed understanding
of the complex DNA damage repair network
and how the interacting pathways may be
rewired in cancers with unstable genomes,
as well as on deeper insights into the diverse
functions of PARPs and how they contribute to
synthetic lethality.
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UnCHKed DNA replication: A stressful matter
Comment on: Llopis A, et al. Cell Cycle 2012; 11:3627–37;
PMID:22935704; http://dx.doi.org/10.4161/cc.21917
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It is easy to conceive that in a toxic environment most cells would abandon the division
process. In the past decades, it has indeed
become clear that cells have developed complex cell cycle checkpoint mechanisms, which
slow-down or stop cells from proliferating
under challenging conditions. More recently,
however, is the discovery and molecular characterization of signaling cascades capable of
integrating classical stress-activated responses
and cell cycle checkpoints. A report published
in a recent issue of Cell Cycle1 sheds light on the
increasing complexity of such pathways. The
authors found that the stress-activated protein kinases p38 and JNK cooperate with Chk1
to block progression into mitosis under conditions that alter DNA replication (i.e., treatments of cells with antiproliferative drugs such
as hydroxyurea, aphidicolin, camptothecin or
etoposide). By using a combination of pharmacological and genetic tools, together with
precise protocols of cell cycle synchronization,
the study shows compelling evidence that
in murine NIH3T3 and embryonic fibroblasts,
hydroxyurea (used at concentrations capable
of abrogating DNA synthesis) added during
progression through S-phase first induces an
early acute activation of Chk1 that is immediately followed by a phasic activation of both
p38 and JNK. Remarkably, p38 and JNK activities are triggered completely independent of
ATM-ATR and Chk1 activation, since their activities were similarly induced in the presence of
caffeine and UCN-01, respectively.
Additionally, activation of p38 under DNA
replication blockade seems to be mediated by
MKK3 and MKK6 (usual kinases turning-on p38
signaling), while interestingly, JNK activation
seems to be exclusively caused by MKK4 (one of
the regular kinases switching-on the JNK pathway) but not MKK7. Furthermore, downstream
of p38 signaling, the authors unveiled activation of MK2 and MK3, kinases classically activated by p38 under many stressors. Strikingly,
activation of MKK3/6-p38-MK2/3 and MKK4JNK cascades in the presence of hydroxyurea
is required to suppress entry into mitosis as
measured by reduced (Serine 10)-histone H3
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Figure 1. A proposed model of signaling circuitry integrating stress-response and cell cycle
checkpoint pathways. Refer to text and references for details.

phospho-signal and impaired (Threonine 14
and Tyrosine 15)-CDK1 dephosphorylation and
activation. The effect on CDK1 activity is likely
mediated by inhibitory regulation of members
of the Cdc25 family of phosphatases (Fig. 1),
as previously reported by others.2-4 Finally, the
authors establish that at least p38α and p38β
are involved in this mechanism; however, it is
still unclear whether JNK1 and JNK2 both play
significant roles in the process. Also, it remains
to be identified which kinase(s) is (are) responsible for the activation of the respective p38
and JNK MKKs, under conditions blocking DNA
synthesis/replication.
On the other hand, some progress has
been made in the identification of substrates
of the stress-activated protein kinases p38
and JNK implicated in DNA replication. Two
recent studies found that Cdt1 is phosphorylated, probably at several residues, by both
p38 and JNK, in the presence of genotoxic5
(UV-C) and non-genotoxic6 (including sorbitol
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and anisomycin) stressors. Cdt1 is a key DNA
replication licensing factor that contributes
with Cdc6 to ensure proper loading of the
MCM complex onto chromatin to form the prereplication complex. Notably, stress-mediated
phosphorylation of Cdt1 blocks its degradation during S-phase,5,6 leads to the dissociation of the histone acetylase HBO1/KAT7 from
replication origins6 and compromises the ability of Cdt1 to instigate loading of the MCM
complex,5 therefore blocking initiation of DNA
replication.5,6
Moreover, JNK was also found to phosphorylate the RING-finger type E3 ubiquitin
ligase Rad18, involved in postreplication repair
of damaged DNA (UV-C irradiation). JNKmediated Rad18 phosphorylation appears to
facilitate recruitment of the translesion synthesis DNA polymerase Polη to stalled replication
forks.7 Polη is then presumably capable of
DNA synthesis over the damaged DNA, later
allowing DNA replication by conventional DNA
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polymerases to occur. This intriguing observation rather suggests a role for JNK in DNA damage response tolerance pathways.
Based on those and other studies describing a direct control of cell cycle regulators by
stress-response pathways, at least in the case
of JNK, it is possible to advocate a general
function in cellular genome integrity maintenance, through the regulation of substrates
such as Cdt1 and Rad18, or histone H3 and
Cdh1/FZR1, under toxic5-7 or unperturbed8,9
conditions, respectively. Finally, according
to our current understanding of the stressactivated signaling pathways, it is noteworthy that the analytical dynamics, subcellular

localization and temporal occurrence of the
stress input (directly associated with cell cycle
checkpoints or not) would likely determine
not only the strength, duration and diffusion
of the stress response but more importantly
its final functional outcome.1 In practical terms,
the modulability of the stress-response could
decide which exact pathways are activated
and which substrates need to be accordingly
modified. Given the growing involvement of
stress responses in the control of cell cycle
(checkpoint) mechanisms, we would speculate
that in coming years, the cell cycle-related
phosphoproteome governed by canonical
stress kinases will continue to augment.
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